Opinion|Videos|February 27, 2025
Treatment Goals for Transitioning From 2L to 3L mRCC
Author(s)Pedro Barata, MD, MSc, FACP
An expert discusses how, in third line (3L) therapy, goals shift from optimal disease control to managing treatment-resistant disease while preserving quality of life. Unlike 2L therapy where significant disease control is still expected, 3L aims for modest clinical benefit, symptomatic relief, and stabilizing disease progression. Treatment choices now heavily prioritize tolerability, patient preferences, and palliative considerations.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What are the goals of therapy going into 3L?
- Do they differ from 2L?
Advertisement
Related to this article
Oncologists weigh second-line options after IO/TKI failure in metastatic ccRCC, highlighting tolerability, mechanism shifts, and belzutifan’s broader role.
The FDA has approved Omcazio, a capsule-based formulation of cabozantinib as a laurylsulfate salt, that demonstrated bioequivalence to the existing tablet.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
A Look Inside CONVERGE: Intratumoral Therapy Comes to Locally Advanced NSCLC
2
DiBardino Outlines Phase 2 CONVERGE Trial Design of Radioenhancer in NSCLC
3
FDA Approves Imlunestrant Plus Abemaciclib in ESR1-Mutated Breast Cancer
4
Taletrectinib Sustains Durable ROS1+ NSCLC Responses at 3-Year Follow-Up
5